Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Acquired by Geode Capital Management LLC

Geode Capital Management LLC increased its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 2.8% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 2,206,800 shares of the biopharmaceutical company's stock after acquiring an additional 59,597 shares during the period. Geode Capital Management LLC owned approximately 1.71% of Alnylam Pharmaceuticals worth $518,367,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of ALNY. National Bank of Canada FI increased its position in shares of Alnylam Pharmaceuticals by 9.0% in the fourth quarter. National Bank of Canada FI now owns 668 shares of the biopharmaceutical company's stock valued at $157,000 after buying an additional 55 shares in the last quarter. Edmond DE Rothschild Holding S.A. acquired a new stake in Alnylam Pharmaceuticals in the 4th quarter valued at $63,000. Allstate Corp purchased a new stake in Alnylam Pharmaceuticals in the 4th quarter worth $894,000. DnB Asset Management AS raised its position in Alnylam Pharmaceuticals by 5.3% during the fourth quarter. DnB Asset Management AS now owns 26,733 shares of the biopharmaceutical company's stock worth $6,291,000 after acquiring an additional 1,335 shares during the period. Finally, Orion Portfolio Solutions LLC lifted its holdings in Alnylam Pharmaceuticals by 5.7% during the fourth quarter. Orion Portfolio Solutions LLC now owns 3,744 shares of the biopharmaceutical company's stock valued at $881,000 after purchasing an additional 203 shares in the last quarter. Hedge funds and other institutional investors own 92.97% of the company's stock.

Remove Ads

Alnylam Pharmaceuticals Trading Up 8.4 %

Shares of ALNY traded up $18.95 during trading on Wednesday, reaching $243.27. 2,100,028 shares of the company traded hands, compared to its average volume of 854,684. The stock has a 50-day simple moving average of $254.83 and a 200-day simple moving average of $258.93. The stock has a market cap of $31.65 billion, a PE ratio of -112.11 and a beta of 0.30. Alnylam Pharmaceuticals, Inc. has a twelve month low of $141.98 and a twelve month high of $304.39. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.03). On average, analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CFO Jeffrey V. Poulton sold 967 shares of the business's stock in a transaction on Friday, February 14th. The shares were sold at an average price of $255.17, for a total value of $246,749.39. Following the completion of the transaction, the chief financial officer now owns 32,786 shares in the company, valued at $8,366,003.62. The trade was a 2.86 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CMO Pushkal Garg sold 52,592 shares of the stock in a transaction on Monday, January 27th. The shares were sold at an average price of $285.00, for a total value of $14,988,720.00. Following the completion of the sale, the chief marketing officer now owns 11,989 shares in the company, valued at approximately $3,416,865. The trade was a 81.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 71,234 shares of company stock worth $19,958,097. 1.50% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of analysts have recently commented on ALNY shares. StockNews.com cut shares of Alnylam Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Friday, March 21st. Royal Bank of Canada boosted their price objective on Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the stock an "outperform" rating in a research note on Friday, March 21st. JPMorgan Chase & Co. raised Alnylam Pharmaceuticals from a "neutral" rating to an "overweight" rating and lifted their price target for the stock from $280.00 to $328.00 in a research note on Monday, March 24th. Citigroup boosted their price target on Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the stock a "buy" rating in a research report on Friday, March 21st. Finally, Sanford C. Bernstein decreased their price objective on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an "outperform" rating on the stock in a report on Tuesday, January 7th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty-one have given a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $316.25.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.